Back to discover

Protein / target

Nuclear factor erythroid 2-related factor 2

Encoded byNFE2L2Q16236Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
1
Approved medicines
Open Targets target-level
Small-molecule tractable
Druggability
Approved Drug
35
Research papers

Protein at a glance

Biological role

Transcription cis-regulatory region binding

Strongest disease association

Carcinoma, Hepatocellular

Via encoding gene NFE2L2 · Literature evidence · score 0.60

Therapeutic position

Established drug target

Small molecules

Research activity

Actively researched

35 papers · latest 2025

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Transcription factor that plays a key role in the response to oxidative stress: binds to antioxidant response (ARE) elements present in the promoter region of many cytoprotective genes, such as phase 2 detoxifying enzymes, and promotes their expression, thereby neutralizing reactive electrophiles.

View complete UniProt function annotation

Transcription factor that plays a key role in the response to oxidative stress: binds to antioxidant response (ARE) elements present in the promoter region of many cytoprotective genes, such as phase 2 detoxifying enzymes, and promotes their expression, thereby neutralizing reactive electrophiles (PubMed:11035812, PubMed:19489739, PubMed:29018201, PubMed:31398338). In normal conditions, ubiquitinated and degraded in the cytoplasm by the BCR(KEAP1) complex (PubMed:11035812, PubMed:15601839, PubMed:29018201). In response to oxidative stress, electrophile metabolites inhibit activity of the BCR(KEAP1) complex, promoting nuclear accumulation of NFE2L2/NRF2, heterodimerization with one of the small Maf proteins and binding to ARE elements of cytoprotective target genes (PubMed:19489739, PubMed:29590092). The NFE2L2/NRF2 pathway is also activated in response to selective autophagy: autophagy promotes interaction between KEAP1 and SQSTM1/p62 and subsequent inactivation of the BCR(KEAP1) complex, leading to NFE2L2/NRF2 nuclear accumulation and expression of cytoprotective genes (PubMed:20452972). The NFE2L2/NRF2 pathway is also activated during the unfolded protein response (UPR), contributing to redox homeostasis and cell survival following endoplasmic reticulum stress (By similarity). May also be involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region (PubMed:7937919). Also plays an important role in the regulation of the innate immune response and antiviral cytosolic DNA sensing. It is a critical regulator of the innate immune response and survival during sepsis by maintaining redox homeostasis and restraint of the dysregulation of pro-inflammatory signaling pathways like MyD88-dependent and -independent and TNF signaling (By similarity). Suppresses macrophage inflammatory response by blocking pro-inflammatory cytokine transcription and the induction of IL6 (By similarity). Binds to the proximity of pro-inflammatory genes in macrophages and inhibits RNA Pol II recruitment. The inhibition is independent of the NRF2-binding motif and reactive oxygen species level (By similarity). Represses antiviral cytosolic DNA sensing by suppressing the expression of the adapter protein STING1 and decreasing responsiveness to STING1 agonists while increasing susceptibility to infection with DNA viruses (PubMed:30158636). Once activated, limits the release of pro-inflammatory cytokines in response to human coronavirus SARS-CoV-2 infection and to virus-derived ligands through a mechanism that involves inhibition of IRF3 dimerization. Also inhibits both SARS-CoV-2 replication, as well as the replication of several other pathogenic viruses including Herpes Simplex Virus-1 and-2, Vaccinia virus, and Zika virus through a type I interferon (IFN)-independent mechanism (PubMed:33009401)

Subcellular location

Cytoplasm, cytosolNucleus
Domains and Gene Ontology detail (65)

Domains & features

bZIP

Gene Ontology

  • Cchromatin
  • Ccytoplasm
  • Ccytosol
  • Cmediator complex
  • Cnucleoplasm
  • Cnucleus
  • Cprotein-DNA complex
  • FDNA binding
  • FDNA-binding transcription activator activity, RNA polymerase II-specific
  • FDNA-binding transcription factor activity
  • FDNA-binding transcription factor activity, RNA polymerase II-specific
  • Fmolecular condensate scaffold activity

605 aa · 68 kDa · 3 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell migrationGOCell proliferation & survivalUniProtTranscriptional regulationUniProt · GOImmune signallingUniProt · GOApoptosis & cell deathGO
View supporting evidence

Cell migration

  • ·negative regulation of vascular associated smooth muscle cell migration
  • ·positive regulation of blood vessel endothelial cell migration

Cell proliferation & survival

  • ·Transcription factor that plays a key role in the response to oxidative stress: binds to…

Transcriptional regulation

  • ·Transcription factor that plays a key role in the response to oxidative stress: binds to…
  • ·DNA-binding transcription activator activity, RNA polymerase II-specific
  • ·DNA-binding transcription factor activity
  • ·DNA-binding transcription factor activity, RNA polymerase II-specific

Immune signalling

  • ·Transcription factor that plays a key role in the response to oxidative stress: binds to…
  • ·regulation of innate immune response
  • ·T cell differentiation

Apoptosis & cell death

  • ·negative regulation of cardiac muscle cell apoptotic process
  • ·negative regulation of endothelial cell apoptotic process

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene NFE2L2

Gene-level evidence surfaced through the gene NFE2L2that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Friedreich Ataxia
0.69Moderately supported

Clinical evidence dominant · Open Targets 0.55

Carcinoma, Hepatocellular
0.58Moderately supported

Somatic mutation evidence dominant · Open Targets 0.60

Urinary Bladder Neoplasms
0.52Moderately supported

Somatic mutation evidence dominant · Open Targets 0.46

Squamous cell lung carcinoma
0.52Moderately supported

Somatic mutation evidence dominant · Open Targets 0.59

Squamous Cell Carcinoma of Head and Neck
0.51Moderately supported

Somatic mutation evidence dominant · Open Targets 0.51

View evidence synthesis (5)
Friedreich AtaxiaModerately supported
0.69
agreement 0.530.84
Clinical85%Literature16%

Open Targets aggregate 0.55 · 2 independent evidence families

Carcinoma, HepatocellularModerately supported
0.58
agreement 0.420.74
Somatic mutation77%Literature23%

Open Targets aggregate 0.60 · 2 independent evidence families

Urinary Bladder NeoplasmsModerately supported
0.52
agreement 0.360.68
Somatic mutation83%Literature18%

Open Targets aggregate 0.46 · 2 independent evidence families

Squamous cell lung carcinomaModerately supported
0.52
agreement 0.360.68
Somatic mutation93%Literature7%

Open Targets aggregate 0.59 · 2 independent evidence families

Squamous Cell Carcinoma of Head and NeckModerately supported
0.51
agreement 0.340.67
Somatic mutation76%Literature24%

Open Targets aggregate 0.51 · 2 independent evidence families

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Carcinoma, Hepatocellular0.60
Squamous cell lung carcinoma0.59
Friedreich Ataxia0.55
Squamous Cell Carcinoma of Head and Neck0.51
Urinary Bladder Neoplasms0.46
Lung carcinoma0.40
Esophageal Squamous Cell Carcinoma0.40
Endometrial Neoplasms0.39

Drug development

2 compounds recorded · 1 approved · 1 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines.

View all recorded compounds (2)
BARDOXOLONE METHYLPhase 3
OMAVELOXOLONEApproval

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesStrong

Approved Drug and High-Quality Ligand support this modality.

AntibodiesEmerging

Feasibility evidence (go cc high conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (uniprot ubiquitination and database ubiquitination) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (6)
SM · Approved DrugSM · High-Quality LigandAB · GO CC high confPR · UniProt UbiquitinationPR · Database UbiquitinationPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Safety-related annotations

Increased, Liver SteatosisAOP-Wikiregulation of transcription factor activityToxCast

Terms indexed against this target in Open Targets' safety data, with their datasource. These are annotations, not causal claims: the direction of effect (whether activation or inhibition is implicated), species and evidence strength are not captured here, so an entry does not mean that modulating this target is known to cause that condition.

Research activity

35 papers · to 2025

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Tang D · Cell research · 2021

Zhang J · Oxidative medicine and cellular longevity · 2016

Kajarabille N · International journal of molecular sciences · 2019

Robledinos-Antón N · Oxidative medicine and cellular longevity · 2019

Recent

Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer.

Ricciuti B · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024

Europe PMC papers linked directly to this protein.